The evolution of mutations in the BCR-ABL1 fusion gene transcript renders CML patients resistant to tyrosine kinase inhibitor (TKI) based therapy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.